New Hope for Fibrolamellar Carcinoma: SUMMIT Trial Findings
Ghassan K. Abou-Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the treatment of patients with fibrolamellar carcinoma.
Related Articles
Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Weight Changes and Heart Failure After Breast Cancer
This cohort study assesses the role of postdiagnosis and prediagnosis in weight gain in individuals with higher risk for cardiac dysfunction.
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC
The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Short Course vs. Long Course for Neoadjuvant Radiation for… : Oncology Times
An abstract is unavailable.
A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology
A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s…
5th Surgical Oncology Advanced Practitioner (SOAP) Conference – MDA – Continuing Education (CE)
MDA, 5th Surgical Oncology Advanced Practitioner (SOAP) Conference, 4/24/2025 7:00:00 AM – 4/26/2025 5:30:00 PM, The SOAP (Surgical Oncology Advanced Practitioner) Conference aims to foster…
FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or Metastatic Gastric/GEJ Cancer
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.